Compounders Research Compare

Dianthus Therapeutics, Inc.(DNTH)

Biotechnology · New York, NY

$87.72-0.32 (-0.36%)

Delayed quote: Oct 6, 2026, 11:30 AM EDT

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

New York, NY

92 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Marino Garcia

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T15:31:45.247Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:31:45.247Z.

Quote observation: 2026-10-06T15:30:30.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,906,563,200
Total debt · period ending 2026-06-30: 1,287,000
Cash · period ending 2026-06-30: 110,549,000
TTM operating income · period ending 2026-06-30: -217,844,000

FMP input reference: 6dae1ed753b385efcb651dd8f32a10b6f9886011747f410ddce9f57bee9a14c9

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

DNTH EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

DNTH Competitors' EV/EBIT Ratio

Dianthus Therapeutics, Inc.

Current

Market Cap

$4.91B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Oruka Therapeutics, Inc.

Market Cap

$4.89B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Mirum Pharmaceuticals, Inc.

Market Cap

$4.91B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Definium Therapeutics, Inc.

Market Cap

$4.75B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LifeStance Health Group, Inc.

Market Cap

$4.68B

EV/EBIT Ratio

59.34x

TTM Avg

192.46x

3Y Avg

192.46x

5Y Avg

192.46x

Merit Medical Systems, Inc.

Market Cap

$5.08B

EV/EBIT Ratio

27.07x

TTM Avg

27.45x

3Y Avg

34.84x

5Y Avg

44.16x

Option Care Health, Inc.

Market Cap

$4.65B

EV/EBIT Ratio

16.91x

TTM Avg

15.96x

3Y Avg

18.18x

5Y Avg

22.57x

Erasca, Inc.

Market Cap

$5.15B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BillionToOne, Inc.

Market Cap

$4.62B

EV/EBIT Ratio

97.38x

TTM Avg

157.20x

3Y Avg

157.20x

5Y Avg

157.20x

Scholar Rock Holding Corporation

Market Cap

$5.23B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Dianthus Therapeutics, Inc. (DNTH)	$4.91B	N/A	N/A	N/A	N/A
Oruka Therapeutics, Inc. (ORKA)vs ›	$4.89B	N/A	N/A	N/A	N/A
Mirum Pharmaceuticals, Inc. (MIRM)vs ›	$4.91B	N/A	N/A	N/A	N/A
Definium Therapeutics, Inc. (DFTX)vs ›	$4.75B	N/A	N/A	N/A	N/A
LifeStance Health Group, Inc. (LFST)vs ›	$4.68B	59.34x	192.46x	192.46x	192.46x
Merit Medical Systems, Inc. (MMSI)vs ›	$5.08B	27.07x	27.45x	34.84x	44.16x
Option Care Health, Inc. (OPCH)vs ›	$4.65B	16.91x	15.96x	18.18x	22.57x
Erasca, Inc. (ERAS)vs ›	$5.15B	N/A	N/A	N/A	N/A
BillionToOne, Inc. (BLLN)vs ›	$4.62B	97.38x	157.20x	157.20x	157.20x
Scholar Rock Holding Corporation (SRRK)vs ›	$5.23B	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics